MHRA launches Women’s Health Programme: Legal comment on FemTech regulation
The Medicines and Healthcare products Regulatory Agency (MHRA) has today launched its Women's Health Programme.
It aims to tackle longstanding gaps in evidence on how the risks and benefits of medicines and medical devices may differ for women.
The announcement, made at the inaugural DIA-MHRA Global Summit in London, follows MHRA analysis showing that pregnant women featured in just 1.1% of UK clinical trial applications submitted between 2019 and 2023, and breastfeeding women in just 0.6%.
The programme forms part of the government's renewed Women's Health Strategy for England, and will bring together patients, researchers, healthcare professionals, and industry to strengthen the evidence base while supporting innovation in women's health technologies.
David Hill, Partner in healthcare and regulation at UK and Ireland law firm Browne Jacobson, said: “One of the UK healthcare market’s distinct offerings internationally is its diverse population and state-based healthcare system that comprises cradle-to-grave patient records, which is why it is a global hub for genomics research and development.
“It should therefore be unimaginable that it doesn’t have a sufficient evidence base to ensure half of the population receive adequate access to diagnostics and treatments, yet unfortunately this is where we find ourselves.
“The MHRA's Women's Health Programme is a welcome step in plugging these gaps, but it will at some stage need to address a regulatory framework that is struggling to keep pace with FemTech innovation.
“FemTech covers a wide range of software, diagnostics and apps focused on women's health, and the sector is growing rapidly. Yet regulation of software-based health tools – not just in the UK but globally – has not kept up with state-of-the-art technology that is advanced enough to actively intervene in a user’s health in a manner more akin to physical medical devices.
“Apps with 'tracking' as their sole purpose fall outside the definition of a medical device, while those explicitly intended to aid contraception or conception do not. But the reality is that women routinely use period trackers as contraceptive aids, exposing them to real risks where those apps are inaccurate or unreliable, including unplanned pregnancy.
“The current rules allow app developers too much latitude to self-define their product as a 'wellness' tool and sidestep regulatory scrutiny – particularly where apps can be developed cheaply, rapidly and downloaded directly to personal devices without any clinical oversight.
“At a recent roundtable in which we brought together FemTech founders, delegates told us that a lack of historical data in women's health, combined with ongoing data bias and underrepresentation, as well as regulatory uncertainty are affecting investment in the sector. Together, these issues create higher perceived risk, greater validation requirements and slower funding decisions.
“Better evidence on women's health is essential. But it must go hand in hand with a regulatory system that is genuinely fit for purpose in the digital age.”
Contact
Dan Robinson
PR & Communications Manager
Dan.Robinson@brownejacobson.com
+44 0330 045 1072